<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32948528</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-790X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMJ case reports</Title>
          <ISOAbbreviation>BMJ Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bickerstaff's brainstem encephalitis associated with anti-GM1 and anti-GD1a antibodies.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e236545</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2020-236545</ELocationID>
        <Abstract>
          <AbstractText>Bickerstaff's brainstem encephalitis (BBE) is a Guillain-Barré syndrome (GBS) spectrum disorder associated with predominantly central nervous system predilection. Patients exhibit a variable constellation of depressed consciousness, bilateral external ophthalmoplegia, ataxia and long tract signs. Although the pathophysiology is not fully understood, it has been associated with anti-GQ1b antibodies in two-thirds of patients. We present a patient with clinical features consistent with BBE and positive anti-GM1 and anti-GD1a antibodies. A diagnostic approach to the acutely unwell patient with brainstem encephalitis is explored in this clinical context with a literature review of the aforementioned ganglioside antibody significance. Intravenous immunoglobulin therapy is highlighted in BBE using up-to-date evidence-based extrapolation from GBS.</AbstractText>
          <CopyrightInformation>© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cleaver</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-9657-5815</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK jonathan.cleaver@nhs.net.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>James</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroradiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chohan</LastName>
            <ForeName>Gurjit</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lyons</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMJ Case Rep</MedlineTA>
        <NlmUniqueID>101526291</NlmUniqueID>
        <ISSNLinking>1757-790X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005732">Gangliosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12707-58-3</RegistryNumber>
          <NameOfSubstance UI="C021298">ganglioside, GD1a</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37758-47-7</RegistryNumber>
          <NameOfSubstance UI="D005677">G(M1) Ganglioside</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005677" MajorTopicYN="N">G(M1) Ganglioside</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005732" MajorTopicYN="N">Gangliosides</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015600" MajorTopicYN="N">Glasgow Coma Scale</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009886" MajorTopicYN="N">Ophthalmoplegia</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">brain stem / cerebellum</Keyword>
        <Keyword MajorTopicYN="N">cranial nerves</Keyword>
        <Keyword MajorTopicYN="N">neuro ITU</Keyword>
        <Keyword MajorTopicYN="N">neurology</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32948528</ArticleId>
        <ArticleId IdType="pmc">PMC7511636</ArticleId>
        <ArticleId IdType="doi">10.1136/bcr-2020-236545</ArticleId>
        <ArticleId IdType="pii">13/9/e236545</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bickerstaff ER, Cloake PCP. 
Mesencephalitis and rhombencephalitis. Br Med J
1951;2:77–81. 10.1136/bmj.2.4723.77</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.2.4723.77</ArticleId>
            <ArticleId IdType="pmc">PMC2069534</ArticleId>
            <ArticleId IdType="pubmed">14848512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bickerstaff ER.
Brain-stem encephalitis; further observations on a Grave syndrome with benign prognosis. Br Med J
1957;1:1384–7. 10.1136/bmj.1.5032.1384</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.1.5032.1384</ArticleId>
            <ArticleId IdType="pmc">PMC1973653</ArticleId>
            <ArticleId IdType="pubmed">13436795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odaka M, Yuki N, Yamada M, et al. . 
Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain
2003;126:2279–90. 10.1093/brain/awg233</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg233</ArticleId>
            <ArticleId IdType="pubmed">12847079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogliun G, Beghi E, Italian GBS Registry Study Group . 
Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand
2004;110:100–6. 10.1111/j.1600-0404.2004.00272.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2004.00272.x</ArticleId>
            <ArticleId IdType="pubmed">15242417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahrizaila N, Yuki N. 
Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry
2013;84:576–83. 10.1136/jnnp-2012-302824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-302824</ArticleId>
            <ArticleId IdType="pubmed">22984203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraci FM, Choi J, Baumbach GL, et al. . 
Microcirculation of the area postrema. Permeability and vascular responses. Circ Res
1989;65:417–25. 10.1161/01.RES.65.2.417</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.65.2.417</ArticleId>
            <ArticleId IdType="pubmed">2752549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Breemen VL, Clemente CD. 
Silver deposition in the central nervous system and the hematoencephalic barrier studied with the electron microscope. J Biophys Biochem Cytol
1955;1:161–6. 10.1083/jcb.1.2.161</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.1.2.161</ArticleId>
            <ArticleId IdType="pmc">PMC2223766</ArticleId>
            <ArticleId IdType="pubmed">14381438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Kusunoki S, Obata H, et al. . 
Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology
1993;43:1911–7. 10.1212/WNL.43.10.1911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.43.10.1911</ArticleId>
            <ArticleId IdType="pubmed">8413947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vajn K, Viljetić B, Degmečić IV, et al. . 
Differential distribution of major brain gangliosides in the adult mouse central nervous system. PLoS One
2013;8:e75720. 10.1371/journal.pone.0075720</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0075720</ArticleId>
            <ArticleId IdType="pmc">PMC3787110</ArticleId>
            <ArticleId IdType="pubmed">24098718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Go T.
Partial oculomotor nerve palsy associated with elevated anti-galactocerebroside and anti-GM1 antibodies. J Pediatr
2000;137:425–6. 10.1067/mpd.2000.107797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mpd.2000.107797</ArticleId>
            <ArticleId IdType="pubmed">10969272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fusco C, Bertani G, Scarano A, et al. . 
Acute ophthalmoparesis associated with anti-GM1, anti-GD1a, and anti-GD1b antibodies after enterovirus infection in a 6-year-old girl. J Child Neurol
2007;22:432–4. 10.1177/0883073807301921</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073807301921</ArticleId>
            <ArticleId IdType="pubmed">17621523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Susuki K, Koga M, et al. . 
Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A
2004;101:11404–9. 10.1073/pnas.0402391101</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0402391101</ArticleId>
            <ArticleId IdType="pmc">PMC509213</ArticleId>
            <ArticleId IdType="pubmed">15277677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verboon C, van den Berg B, Cornblath DR, et al. . 
Original research: second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry
2020;91:113–21. 10.1136/jnnp-2019-321496</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2019-321496</ArticleId>
            <ArticleId IdType="pubmed">31586949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Jacobs BC, Lingsma HF, et al. . 
Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst
2018;23:210–5. 10.1111/jns.12286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns.12286</ArticleId>
            <ArticleId IdType="pubmed">30151941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. . 
Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol
2009;66:597–603. 10.1002/ana.21737</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21737</ArticleId>
            <ArticleId IdType="pubmed">19938102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ.
Gangliosides as targets for autoimmune injury to the nervous system. J Neurochem
2007;103(Suppl 1):143–9. 10.1111/j.1471-4159.2007.04718.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2007.04718.x</ArticleId>
            <ArticleId IdType="pubmed">17986149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rayamajhi A, Nightingale S, Bhatta NK, et al. . 
Correction: a preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One
2015;10:e0136008. 10.1371/journal.pone.0136008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0136008</ArticleId>
            <ArticleId IdType="pmc">PMC4536009</ArticleId>
            <ArticleId IdType="pubmed">26270465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iro MA, Sadarangani M, Absoud M, et al. . 
Immunoglobulin in the treatment of encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial. BMJ Open
2016;6:e012356. 10.1136/bmjopen-2016-012356</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2016-012356</ArticleId>
            <ArticleId IdType="pmc">PMC5129051</ArticleId>
            <ArticleId IdType="pubmed">27810972</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
